High Risk Prostate Cancer - Updates Webinar

There are many ongoing advances in the management of high risk and locally advanced prostate cancer, including concepts of systemic therapy intensification and de-escalation, dose escalation, and the use of biomarkers. It is imperative that the radiation oncology professional remain current in the management of high-risk and locally advanced prostate cancer. This activity will provide participants the opportunity to gain exposure to the latest science in radiation oncology, urologic oncology and medical oncology as they pertain to our practice. 

We will review recent developments in the multi-disciplinary management of high-risk or locally advanced prostate cancer. Specific areas of discussion include systemic therapy intensification, dose escalation, pelvic nodal radiotherapy, and biomarker-based approaches. 

Topics:

  1. High Risk Prostate Cancer Updates
    Amar U. Kishan, MD
  2. High Risk Prostate Cancer Updates - Urology Perspective
    Declan Murphy, MD
  3. Q and A/Discussion
    Neha Vapiwala, MD, FASCO, FASTRO - Moderator
    Amar U. Kishan, MD
    Declan Murphy, MD

This content is presented as a live webinar on July 20, 2026. 

This activity will be available from July 20, 2026 to July 19, 2028.

Continuing education credit is available for this activity until August 20, 2026.

Target Audience

The activity is designed to meet the interests of medical oncologists, radiation oncologists and surgeons. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the evidence for systemic therapy intensification with definitive radiotherapy for high-risk or locally advanced prostate cancer. 
  • Discuss the evidence for incorporating biomarkers in the management of high-risk or locally advanced prostate cancer.
  •  
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
06/26/2026
Course expires: 
06/25/2028
Cost:
$49.00
Rating: 
0

High Risk Prostate Cancer Updates

  • Amar U. Kishan, MD

It is imperative that radiation oncology professionals 

High Risk Prostate Cancer Updates - Urology Perspective

  • Declan Murphy, MD

In this presentation we provide an overview of the 

Moderator:

  • Neha Vapiwala, MD, FASCO, FASTRO, is employed by the University of Pennsylvania. Dr. Vapiwala has no relevant financial relationship with ineligible companies to disclose. 

Speakers:

  • Amar U. Kishan, MD, is employed by UCLA. Dr. Kishan receives grant/research funding and/or honoraria from Varian Medical Systems, Inc., Janssen, Inc., Point BioPharma, Boston Scientific, Inc., Lantheus, Novartis, MiraDx and ViewRay Systems, Inc. 
  • Declan Murphy, MD, is employed by the Peter MacCallum Cancer Centre.  

Planners:

  • Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies. 
  • Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies. 
  • Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
  • Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems. 
  • Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical. 

All relevant financial relationships have been mitigated.

The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Continuing education credits for this activity must be claimed by August 20, 2026 by completing the evaluation.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™

    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$49.00
Please login or register to take this course.

Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.

  • Nonmember: $49
  • Member: $0
  • Member-in-Training: $0
  • Student/Graduate Student/PGY-1 Member: $0
  • Postdoctoral Fellow Member: $0

Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date. 

Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.

The activity and its materials will only be available on the ASTRO website until July 19, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date. 

Required Hardware/software

One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.